A specific mission:
Provide Easy and Rapid Access to Circulating Rare Cells
Screencell is dedicated to creating technologies allowing CTCs to become potential end points in future oncology therapeutic arsenals, by filtering out healthy live tumor cells, thus enabling:
■ molecular biology
■ cell culture
■ enumeration and cytomorphology evaluation
The technology has also demonstrated its advantages for the isolation of Circulating Fetal Cells (CFCs) drawn from peripheral blood of pregnant women, potentially leading to a significantly facilitated and cost- effective process for prenatal diagnosis of genetic diseases.
Collaborations with the Dana-Farber Cancer Institute, and Massachusetts General Hospital, in the USA, Hôpital Saint-Louis, Hôpital Antoine-Béclère, Hôpital Necker and Hôpital de Poissy. in France, and others have proven that today ScreenCell devices are best and most user friendly CTC/CFC isolation devices available.
Our identity is based upon down-to-earth values which guide our daily actions:
■ A deep conviction
Non-invasive access to tumor cells through peripheral blood is a major issue for a better monitoring of patients with cancer
■ An ultimate goal: the patient
We are committed to keeping a view that the patient must be the ultimate goal of our technical developments
■ Integrity and respect
We are committed to integrity, full transparency and respect for our customers, colleagues, and shareholders as a basis for improvement